REG - Hutchmed China Ltd - 2022 Annual Report and Notice of AGM

HUTCHMED (China)Announcement

11/04/2023 09:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230411:nRSK4693Va&default-theme=true

RNS Number : 4693V  Hutchmed (China) Limited  11 April 2023

 

 

2022 Annual Report and Notice of Annual General Meeting

 

Hong Kong, Shanghai, & Florham Park, NJ - Tuesday, April 11, 2023:
HUTCHMED (China) Limited ("HUTCHMED (https://www.hutch-med.com/) ")
(Nasdaq/AIM: HCM; HKEX: 13) today announces that its 2022 Annual Report
together with the Notice of Annual General Meeting and the Form of Proxy ("AGM
Materials") will be posted to shareholders on April 12, 2023 who have elected
to receive the AGM Materials in printed form. The documents can also be
accessed from the HUTCHMED website (www.hutch-med.com
(https://www.hutch-med.com/) ).

 

The 2023 Annual General Meeting ("AGM") will be an electronic/hybrid meeting
to be held at 1st Floor, Harbour Grand Kowloon, 20 Tak Fung Street, Hung Hom,
Kowloon, Hong Kong on Friday, May 12, 2023 at 5:00 pm Hong Kong Time (10:00 am
London Time), with online access through an online platform as detailed in the
AGM Materials.

 

About HUTCHMED

HUTCHMED (Nasdaq/AIM: HCM; HKEX: 13) is an innovative, commercial-stage,
biopharmaceutical company. It is committed to the discovery and global
development and commercialization of targeted therapies and immunotherapies
for the treatment of cancer and immunological diseases. It has more than 5,000
personnel across all its companies, at the center of which is a team of about
1,800 in oncology/immunology. Since inception HUTCHMED has focused on bringing
drug candidates from in-house discovery to patients around the world, with its
first three oncology drugs now approved and marketed in China. For more
information, please visit: www.hutch-med.com (https://www.hutch-med.com/) or
follow us on LinkedIn (https://www.linkedin.com/company/hutchmed/) .

 

CONTACTS
 Investor Enquiries
 Mark Lee, Senior Vice President                    +852 2121 8200
 Annie Cheng, Vice President                        +1 (973) 306 4490

 Media Enquiries
 Americas - Brad Miles,                             +1 (917) 570 7340 (Mobile)

Solebury Trout                                    bmiles@troutgroup.com (mailto:bmiles@troutgroup.com)
 Europe - Ben Atwell / Alex Shaw,                   +44 20 3727 1030 / +44 7771 913 902 (Mobile) /

FTI Consulting                                    +44 7779 545 055 (Mobile)
                                                    HUTCHMED@fticonsulting.com (mailto:HUTCHMED@fticonsulting.com)
 Asia - Zhou Yi,                                    +852 9783 6894 (Mobile)

Brunswick                                         HUTCHMED@brunswickgroup.com (mailto:HUTCHMED@brunswickgroup.com)

 Nominated Advisor
 Atholl Tweedie / Freddy Crossley, Panmure Gordon   +44 (20) 7886 2500

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOAFIFSTSAIEIIV